About SPRAVATO® for Treatment-Resistant Depression (TRD)

Proven efficacy with a consistent safety profile^1,2
Safety evaluated in over 1700 adults with treatment-resistant depression (TRD) across six studies: Five Phase 3 studies and one Phase 2 dose ranging study²

Person in circle purple icon

Click here to review SPRAVATO® indications and patient stories

SPRAVATO® Nasal Spray Device

References:

1. Data on File. RF-210004. Janssen Pharmaceuticals, Inc.

2. SPRAVATO® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. July 2020.